Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> HDAC>>J22352

J22352

Catalog No.GC34629

J22352 est un inhibiteur HDAC6 de type PROTAC (protéolyse-ciblage des chimères) et hautement sélectif avec une valeur IC50 de 4,7 nM. J22352 favorise la dégradation de HDAC6 et induit des effets anticancéreux en inhibant l'autophagie et en déclenchant la réponse immunitaire antitumorale dans les cancers du glioblastome, et en conduisant À la restauration de l'activité antitumorale de l'hÔte en réduisant l'activité immunosuppressive de PD-L1.

Products are for research use only. Not for human use. We do not sell to patients.

J22352 Chemical Structure

Cas No.: 2252395-44-9

Taille Prix Stock Qté
10mM (in 1mL DMSO)
119,00 $US
En stock
5mg
108,00 $US
En stock
10mg
171,00 $US
En stock
50mg
495,00 $US
En stock
100mg
846,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1[1]. HDAC6|4.7 nM (IC50)

J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner[1]. J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance[1]. Cell Viability Assay[1] Cell Line: U87MG cells

J22352 (10mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate. J22352 is well tolerated in mice[1]. Animal Model: Male nude mice (BALB/cAnN.Cg-Foxnlnu/CrlNarl, 4-6 weeks old)[1]

[1]. Liu JR, et al. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Biochem Pharmacol. 2019 May; 163:458-471.

Avis

Review for J22352

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for J22352

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.